FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946585> ?p ?o ?g. }

• W4361946585 abstract "<div>Abstract<p><b>Purpose:</b> Pathogenic <i>POLE</i> proofreading domain mutations are found in many malignancies where they are associated with ultramutation and favorable prognosis. The extent to which this prognosis depends on their sensitivity to adjuvant treatment is unknown, as is the optimal therapy for advanced-staged or recurrent <i>POLE</i>-mutant cancers.</p><p><b>Experimental Design:</b> We examined the recurrence-free survival of women with <i>POLE</i>-mutant and <i>POLE–</i>wild-type endometrial cancers (EC) in the observation arm of the randomized PORTEC-1 endometrial cancer trial (<i>N</i> = 245 patients with stage I endometrial cancer for analysis). Sensitivity to radiotherapy and selected chemotherapeutics was compared between <i>Pole</i>-mutant mouse-derived embryonic stem (mES) cells, generated using CRISPR-Cas9 (<i>Pole</i> mutations D275A/E275A, and cancer-associated P286R, S297F, V411L) and isogenic wild-type cell lines.</p><p><b>Results:</b> In the observation arm of the PORTEC-1 trial (<i>N</i> = 245), women with <i>POLE</i>-mutant endometrial cancers (<i>N</i> = 16) had an improved recurrence-free survival (10-year recurrence-free survival 100% vs. 80.1% for <i>POLE–</i>wild-type; HR, 0.143; 95% confidence interval, 0.001–0.996; <i>P</i> = 0.049). <i>Pole</i> mutations did not increase sensitivity to radiotherapy nor to chemotherapeutics in mES cells. In contrast, <i>Pole</i>-mutant cells displayed significantly increased sensitivity to cytarabine and fludarabine (IC₅₀ <i>Pole</i> P286R–mutant vs. wild-type: 0.05 vs. 0.17 μmol/L for cytarabine, 4.62 vs. 11.1 μmol/L for fludarabine; <i>P</i> < 0.001 for both comparisons).</p><p><b>Conclusions:</b> The favorable prognosis of <i>POLE</i>-mutant cancers cannot be explained by increased sensitivity to currently used adjuvant treatments. These results support studies exploring minimization of adjuvant therapy for early-stage <i>POLE</i>-mutant cancers, including endometrial and colorectal cancers. Conversely, <i>POLE</i> mutations result in hypersensitivity to nucleoside analogues, suggesting the use of these compounds as a potentially effective targeted treatment for advanced-stage <i>POLE</i>-mutant cancers. <i>Clin Cancer Res; 24(13); 3197–203. ©2018 AACR</i>.</p></div>" @default.
• W4361946585 created "2023-04-05" @default.
• W4361946585 creator A5007581278 @default.
• W4361946585 creator A5023906981 @default.
• W4361946585 creator A5025042206 @default.
• W4361946585 creator A5029183739 @default.
• W4361946585 creator A5031287245 @default.
• W4361946585 creator A5040598662 @default.
• W4361946585 creator A5066158380 @default.
• W4361946585 creator A5069612368 @default.
• W4361946585 creator A5072877422 @default.
• W4361946585 creator A5083838208 @default.
• W4361946585 creator A5091322627 @default.
• W4361946585 date "2023-03-31" @default.
• W4361946585 modified "2023-10-01" @default.
• W4361946585 title "Data from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues" @default.
• W4361946585 doi "https://doi.org/10.1158/1078-0432.c.6527640" @default.
• W4361946585 hasPublicationYear "2023" @default.
• W4361946585 type Work @default.
• W4361946585 citedByCount "0" @default.
• W4361946585 crossrefType "posted-content" @default.
• W4361946585 hasAuthorship W4361946585A5007581278 @default.
• W4361946585 hasAuthorship W4361946585A5023906981 @default.
• W4361946585 hasAuthorship W4361946585A5025042206 @default.
• W4361946585 hasAuthorship W4361946585A5029183739 @default.
• W4361946585 hasAuthorship W4361946585A5031287245 @default.
• W4361946585 hasAuthorship W4361946585A5040598662 @default.
• W4361946585 hasAuthorship W4361946585A5066158380 @default.
• W4361946585 hasAuthorship W4361946585A5069612368 @default.
• W4361946585 hasAuthorship W4361946585A5072877422 @default.
• W4361946585 hasAuthorship W4361946585A5083838208 @default.
• W4361946585 hasAuthorship W4361946585A5091322627 @default.
• W4361946585 hasBestOaLocation W43619465852 @default.
• W4361946585 hasConcept C121608353 @default.
• W4361946585 hasConcept C126322002 @default.
• W4361946585 hasConcept C2777088508 @default.
• W4361946585 hasConcept C502942594 @default.
• W4361946585 hasConcept C71924100 @default.
• W4361946585 hasConceptScore W4361946585C121608353 @default.
• W4361946585 hasConceptScore W4361946585C126322002 @default.
• W4361946585 hasConceptScore W4361946585C2777088508 @default.
• W4361946585 hasConceptScore W4361946585C502942594 @default.
• W4361946585 hasConceptScore W4361946585C71924100 @default.
• W4361946585 hasLocation W43619465851 @default.
• W4361946585 hasLocation W43619465852 @default.
• W4361946585 hasOpenAccess W4361946585 @default.
• W4361946585 hasPrimaryLocation W43619465851 @default.
• W4361946585 hasRelatedWork W2127503099 @default.
• W4361946585 hasRelatedWork W2335425347 @default.
• W4361946585 hasRelatedWork W2365364931 @default.
• W4361946585 hasRelatedWork W2418638721 @default.
• W4361946585 hasRelatedWork W2734526255 @default.
• W4361946585 hasRelatedWork W2891666204 @default.
• W4361946585 hasRelatedWork W3121488219 @default.
• W4361946585 hasRelatedWork W3128348746 @default.
• W4361946585 hasRelatedWork W3144668473 @default.
• W4361946585 hasRelatedWork W4238850057 @default.
• W4361946585 isParatext "false" @default.
• W4361946585 isRetracted "false" @default.
• W4361946585 workType "article" @default.